One week after securing its ownership of the Parkinson's drug fipamezole, Santhera Pharmaceuticals Holding AG secured a partner for the compound, in the shape of Biovail Corp., which could end up paying the Swiss firm as much as $192 million in up-front, development, regulatory and commercial milestones for North American rights to the drug. (BioWorld Today)
NeuroSearch A/S will bank as much as €32 million (US$45.1 million) in guaranteed funding over the next three years on the strength of a new drug discovery and development alliance in central nervous system disease with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson Co., of New Brunswick, N.J. (BioWorld International)
Shares in Genmab A/S dropped sharply Tuesday on news that its anti-CD20 antibody ofatumumab failed to demonstrate a significant objective response rate in non-Hodgkins lymphoma (NHL) patients who were refractory to other treatments. (BioWorld Today)
Almost a full year after Pfizer Inc. decided to discontinue development of PF-03187207, it finally handed the compound back to its erstwhile partner, NiCox SA, and has withdrawn from its strategic alliance in ophthalmology with the company. (BioWorld International)
No Abstract BioWorld International CorrespondentOncodesign SA is heading up a cancer biomarker consortium that has secured €10 million (US$14.1 million) from the French innovation agency OSEO to develop a new generation of tumor-specific radiotracers.
